Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YF550 in Locally Advanced or Metastatic Solid Tumors
NCT07894874Phase 1Not yet recruiting
- Sponsor
- Yiqi Biotechnology (Beijing)
- Start
- Oct 2026
- Primary completion
- Jan 2029
01
Overview
Phase 1, open-label, single-arm trial of YF550 in solid tumor, ovarian cancer, non-small cell lung cancer (NSCLC) and 1 more, sponsored by Yiqi Biotechnology (Beijing). Primary endpoints: Treatment-emergent adverse events, Dose-limiting toxicities at 21 days and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
YF550
03
Conditions
solid tumorovarian cancernon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07894874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894874.